Hoth Therapeutics announced that it has received written approval from the University of Texas MD Anderson Cancer Center Institutional Review Board, or IRB, to proceed with its First-in-Human, or FIH, Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors, or EGFRi. This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on HOTH:
- Hoth Therapeutics files $25M mixed securities shelf
- Hoth Therapeutics Soars on Promising Data in Alzheimer’s Disease
- Hoth Therapeutics’ Merger Plans Fall Flat with Shareholders
- Hoth Therapeutics and Algorithm Sciences execute Letter of Intent to merge
- Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge